
Explore a new treatment option for symptomatic obstructive HCM

Visit us at BMS **BOOTH 116**

The FDA recently approved a treatment option for appropriate patients with symptomatic NYHA Class II–III obstructive HCM. Learn about the MOA, examine the endpoints, and read about the safety profile of this treatment option at BMS Booth 116.

FDA=US Food and Drug Administration; HCM=hypertrophic cardiomyopathy; MOA=mechanism of action; NYHA=New York Heart Association.